Protein degraders are a class of drugs designed to destroy disease-causing proteins rather than merely blocking their activity. Traditional medicines work like a key jammed into a lock, sitting in a protein’s active site and preventing it from doing its job. Degraders take a fundamentally different approach: they hijack the cell’s own waste-disposal machinery to tag a target protein for destruction and then recycle themselves to do it again. The distinction has massive implications for diseases driven by proteins that conventional drugs cannot touch.
How Your Cells Already Destroy Proteins
Every cell continuously breaks down proteins it no longer needs. The primary system responsible for this cleanup is the ubiquitin-proteasome system, or UPS. In simple terms, when a protein is marked for removal, the cell attaches small molecular tags called ubiquitin chains to it through a cascade of enzymes, the last of which is an E3 ubiquitin ligase. Once a protein is decorated with enough ubiquitin, a barrel-shaped structure called the proteasome recognizes the tags, pulls the protein in, and chops it into fragments the cell can reuse.1PubMed Central. Ubiquitin proteasome system in immune regulation and therapeutics
Protein degrader drugs exploit this existing system. They do not introduce foreign machinery into the cell. Instead, they redirect the cell’s own quality-control apparatus toward a protein of the researcher’s choosing. Think of it as social engineering at the molecular level: the degrader convinces the cell’s recycling crew to pick up a specific piece of equipment that was never flagged for disposal.
PROTACs and the Ternary Complex
The most widely studied type of protein degrader is called a PROTAC, short for proteolysis-targeting chimera. A PROTAC is a small molecule with two functional ends connected by a chemical linker. One end grabs the target protein. The other end grabs an E3 ubiquitin ligase. When both ends bind simultaneously, the target protein and the E3 ligase are pulled into close proximity, forming what researchers call a ternary complex.2PubMed Central. A suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands Once the three players are assembled, the E3 ligase does what it normally does: it tags the target protein with ubiquitin, after which the proteasome takes over and destroys it.
A crucial detail is that the PROTAC itself is not consumed in this process. After the target protein is tagged and released for destruction, the PROTAC molecule is free to recruit another copy of the target protein. This catalytic behavior means a single PROTAC molecule can trigger the degradation of multiple target proteins over time, which allows these drugs to work at far lower concentrations than traditional inhibitors. Some PROTACs show activity in the nanomolar to picomolar range.3PubMed Central. Inhibitors to degraders: Changing paradigm in drug discovery
Why Ternary Complex Stability Matters So Much
Not all ternary complexes are created equal. A PROTAC might bind its target protein strongly on one end and its E3 ligase strongly on the other, yet still fail as a degrader if the three-way assembly falls apart too quickly for ubiquitin tagging to occur. Researchers have found that ternary complexes vary dramatically in how long they last and how tightly they hold together, and these differences directly predict how well a PROTAC degrades its target.4PubMed Central. SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate
The key concept here is cooperativity. When the three-way binding is positively cooperative, the presence of the target protein on one arm of the PROTAC makes the E3 ligase bind more tightly on the other arm, and vice versa. This produces a stable, long-lived complex that gives the ligase enough time to do its job. Negative cooperativity has the opposite effect, destabilizing the complex and reducing degradation efficiency.5ACS Bio & Med Chem Au. Modeling the Effect of Cooperativity in Ternary Complex Formation and Targeted Protein Degradation Mediated by Heterobifunctional Degraders Even a single amino acid difference between closely related target proteins can flip a stable complex into an unstable one, which explains why some PROTACs can selectively degrade one family member while leaving a nearly identical sibling untouched.4PubMed Central. SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate
Molecular Glues, the Simpler Alternative
PROTACs are not the only game in town. Molecular glues are smaller, simpler molecules that work by a subtly different trick. Instead of bridging two proteins with a linker, a molecular glue binds to an E3 ligase and reshapes its surface so that a target protein suddenly sticks to it. The target protein was never a natural substrate of that ligase, but the glue creates a new protein-protein interaction where none existed before.6PubMed Central. Molecular glues: Recent advances in cereblon substrate identification and mechanistic insights
The most famous molecular glues are immunomodulatory drugs like thalidomide and its derivatives lenalidomide and pomalidomide, which recruit the E3 ligase cereblon (CRBN) to degrade specific proteins. What makes glues attractive is their smaller size, which generally gives them better drug-like properties, including easier absorption when taken as a pill. Their limitation has historically been that discovering them was largely accidental. Rational design of molecular glues is now advancing, though, with researchers identifying new substrates and unconventional recognition modes that were not anticipated from the original thalidomide-era findings.6PubMed Central. Molecular glues: Recent advances in cereblon substrate identification and mechanistic insights Plant hormones like auxin are natural molecular glues, hinting that evolution stumbled onto this degradation strategy long before pharmaceutical chemists did.7Biochemical Society Transactions. Lessons from natural molecular glue degraders
Reaching Proteins That Conventional Drugs Cannot
The single biggest reason protein degraders generate so much excitement is their potential to go after targets that traditional small-molecule drugs cannot touch. An estimated 85% of human proteins lack the kind of well-defined binding pocket that a conventional inhibitor needs. Transcription factors, scaffolding proteins, and many signaling proteins fall into this “undruggable” category, and they include some of the most consequential drivers of cancer and other diseases.
PROTACs change the rules because they do not need to block a protein’s activity. They just need to grab onto it somewhere, anywhere, well enough to bring it close to an E3 ligase. A shallow groove or a small surface patch that would be useless for inhibition can be perfectly adequate for recruitment. Researchers have shown particular promise targeting transcription factors, which regulate gene expression and are implicated in many cancers. Because transcription factors recognize short DNA sequences, some groups have even used short DNA-like molecules as the target-binding arm of a PROTAC.8Journal of Medicinal Chemistry. Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives
Most PROTACs developed so far recruit just a handful of E3 ligases, primarily VHL and CRBN. The human genome encodes over 600 E3 ligases, meaning the vast majority remain untapped. Recent efforts to recruit novel E3 ligases beyond this established quartet are opening new avenues for tissue-selective degradation and expanded target coverage.9Targets. The Expanding E3 Ligase-Ligand Landscape for PROTAC Technology
Beyond the Proteasome
The ubiquitin-proteasome system handles most intracellular protein disposal, but many disease-relevant targets live outside the cell or sit embedded in the cell membrane, where the proteasome cannot reach them. A wave of newer degrader platforms tackles these targets by exploiting different disposal routes.
Lysosome-targeting chimeras, or LYTACs, work by recruiting extracellular or membrane-bound proteins to cell-surface receptors that shuttle cargo into lysosomes, the cell’s acidic digestion chambers. Antibody-based PROTACs (AbTACs) use a similar strategy with an antibody scaffold. Together, these technologies extend targeted protein degradation to secreted proteins and receptors that PROTACs alone cannot address.10PubMed Central. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins11Cell Chemical Biology. Protein Degraders: How They Work and Why They Matter
Another family of approaches bypasses the proteasome entirely by routing targets into autophagy, the cell’s bulk recycling process. Platforms like ATTEC (autophagosome-tethering compounds), AUTAC (autophagy-targeting chimeras), and AUTOTAC each connect a target to the autophagy machinery in slightly different ways. These are particularly appealing for large protein aggregates that would not fit through a proteasome’s narrow barrel, making them potentially useful for neurodegenerative diseases characterized by clumps of misfolded protein.12PubMed Central. Targeted Degradation Technologies Utilizing Autophagy
The degradation concept has even been extended to RNA. RIBOTACs are chimeric molecules that recruit an RNA-cleaving enzyme to a specific RNA target, triggering its destruction. A recent example used a nanobody to deliver a RIBOTAC selectively to pancreatic cancer cells, achieving about 60% knockdown of a disease-associated RNA in tumor tissue while sparing normal tissue entirely.13PubMed Central. Cell-Selective Delivery of RIBOTACs via an Anti-EGFR Nanobody for Pancreatic Cancer Treatment
Where Degraders Are Headed in the Clinic
The clinical pipeline for protein degraders is concentrated in oncology, where the need for new approaches is greatest. One of the most advanced applications targets the estrogen receptor (ER) in metastatic breast cancer. Many patients with ER-positive breast cancer eventually develop resistance to standard hormone therapies that block or reduce estrogen signaling. Rather than merely blocking the receptor, PROTAC-based ER degraders aim to eliminate it from the cell altogether, potentially overcoming resistance mechanisms that depend on the receptor still being present. Early clinical studies have shown initial success with this approach.14PubMed Central. Clinician’s guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer
Beyond cancer, neurodegenerative diseases represent a frontier with enormous potential and enormous difficulty. A key pathological protein in Parkinson’s disease is alpha-synuclein, which forms toxic aggregates in neurons. Researchers have designed PROTACs that target alpha-synuclein for proteasomal destruction and demonstrated that these molecules reduce both the protein itself and the aggregates associated with toxicity in cellular and animal models.15PubMed Central. Targeted degradation of α-synuclein by arginine-based PROTACs Getting degrader molecules across the blood-brain barrier remains a formidable challenge, but the fact that degradation can clear protein aggregates rather than just prevent new ones from forming makes the concept compelling for conditions where aggregation is already underway.
The Oral Bioavailability Problem
If you have ever looked at the molecular structure of a PROTAC, you would immediately see the problem. These molecules are big. A typical small-molecule drug weighs under 500 daltons and follows well-established rules about size, flexibility, and chemical properties that predict whether a pill will be absorbed through the gut lining. PROTACs routinely weigh 700 to 1,000 daltons and break several of these traditional rules.
The good news is that the old cutoffs turn out to be more flexible than many chemists assumed. A systematic analysis of PROTAC absorption found that molecules up to about 950 daltons could still achieve meaningful oral absorption, provided other properties stayed in range. The study identified several practical boundaries: no more than two hydrogen-bond donors that are not internally satisfied, a topical polar surface area under roughly 200 square angstroms, and no more than 14 rotatable bonds.16Journal of Medicinal Chemistry. Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders These expanded rules give medicinal chemists room to design PROTACs that can be taken as pills rather than infusions, but the design constraints are tight, and not every target-ligase combination will yield an orally available molecule.
How Cancer Cells Fight Back
Resistance is an inescapable reality in cancer therapy, and degraders are not immune. Interestingly, the way cancer cells develop resistance to PROTACs often differs from how they resist conventional drugs. Rather than mutating the target protein so the drug no longer binds, resistant cells tend to sabotage the E3 ligase machinery itself. In studies of BET-targeting PROTACs, cells that became resistant did so primarily through genomic alterations in components of the E3 ligase complex. Cells resistant to a VHL-based PROTAC harbored mutations and deletions in the CUL2 gene, which encodes a critical scaffold protein in the VHL complex. Cells resistant to a CRBN-based PROTAC carried a large chromosomal deletion that eliminated the CRBN gene altogether.17Molecular Cancer Therapeutics. Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
This pattern carries a practical implication: resistance to one PROTAC that uses a particular E3 ligase would not necessarily confer resistance to a different PROTAC targeting the same protein through a different E3 ligase. The expanding repertoire of recruitable ligases may therefore offer a way to outrun resistance by switching the degradation machinery a drug relies on.
Selectivity, Off-Target Degradation, and the Thalidomide Warning
Destroying proteins is a powerful tool, but it comes with a responsibility that conventional inhibitors do not face. When a traditional drug releases its target, the target protein is still there and can resume function. When a degrader eliminates a protein, it is gone until the cell makes more. If the degrader accidentally tags the wrong protein for destruction, the consequences can be severe, because you cannot undo degradation the way you can reverse a blockade.
The cautionary tale here is thalidomide. Prescribed as a sedative in the late 1950s, thalidomide caused devastating birth defects because it works as a molecular glue that redirects the CRBN E3 ligase to degrade unintended substrates. Researchers have since identified several of these neosubstrates, including the transcription factors SALL4 and p63, as likely mediators of the drug’s teratogenic effects.18PubMed Central. Molecular Mechanisms of the Teratogenic Effects of Thalidomide Modern CRBN-recruiting degraders are designed to be far more selective, but the lesson from thalidomide is that every degrader must be rigorously screened for off-target protein destruction.
New proteomics methods are making that screening more precise. One approach, called DegMS, uses mass spectrometry to distinguish proteins that are directly degraded by a molecule from those whose levels drop indirectly because the cell’s gene expression has changed in response to losing the primary target.19Cell Chemical Biology. Degradome analysis to identify direct protein substrates of small-molecule degraders This kind of fine-grained profiling is becoming standard practice for any degrader headed toward the clinic, precisely because the stakes of getting selectivity wrong are higher than for a drug that merely blocks rather than destroys.
Why the Field Keeps Expanding
What makes targeted protein degradation unusual as a drug-discovery strategy is that it is not one technology. It is a design philosophy applied to multiple cellular disposal routes, each suited to different target classes. PROTACs handle intracellular proteins accessible to the proteasome. LYTACs and AbTACs cover extracellular and membrane targets. Autophagy-based platforms can clear aggregates too bulky for the proteasome. RIBOTACs move the concept from protein to RNA. Each new platform opens a slice of biology that was previously beyond pharmacological reach.
The pace of expansion is reflected in patent filings, startup formation, and licensing deals, but what matters more to patients is that several degrader drugs have moved into human trials over the past few years, with early readouts in breast cancer, prostate cancer, and lymphoma generating enough positive signals to sustain momentum. Whether degraders fulfill their promise will depend on practical challenges, including oral bioavailability, tissue selectivity, managing off-target effects, and staying ahead of resistance. But the underlying logic of coopting a cell’s own destruction machinery, rather than trying to build a better blockade, has proven sound enough that the question is no longer whether degraders will matter, but how many diseases they will eventually reach.